In a report released yesterday, Raj Denhoy from Jefferies reiterated a Buy rating on Insulet Corp (NASDAQ: PODD), with a price target of $97. The company’s shares closed yesterday at $85.89.
According to TipRanks.com, Denhoy is a top 100 analyst with an average return of 20.4% and a 71.9% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Edwards Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet Corp with a $102 average price target, a 18.8% upside from current levels. In a report released yesterday, Northland Securities also maintained a Buy rating on the stock with a $100 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $102.89 and a one-year low of $51.36. Currently, Insulet Corp has an average volume of 698.8K.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is an innovative medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Billerica, MA.
